Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Indolepropionic acid - ViroPharma Incorporated

Drug Profile

Indolepropionic acid - ViroPharma Incorporated

Alternative Names: IN-OX1; Indole-3-propionic acid; IPA - ViroPharma Incorporated; OX-1; Oxigon; SHP 22; SHP-622; VP-20629

Latest Information Update: 02 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator New York University; University of South Alabama
  • Developer Intellect Neurosciences; ViroPharma Incorporated
  • Class Antidementias; Indoles; Neuroprotectants; Propionic acids; Small molecules
  • Mechanism of Action Amyloid inhibitors; Antioxidants; Chelating agents; Free radical scavengers; Protein aggregation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Alzheimer's disease; Friedreich's ataxia

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Friedreich's ataxia in USA (PO, Capsule)
  • 01 Jul 2015 Shire ViroPharma completes a phase I trial in Friedreich's ataxia in USA (NCT01898884)
  • 11 Mar 2014 ViroPharma is now called Shire ViroPharma
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top